Q
Qian Sheng Yu
Researcher at National Institutes of Health
Publications - 29
Citations - 2521
Qian Sheng Yu is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Butyrylcholinesterase & Neuroprotection. The author has an hindex of 23, co-authored 29 publications receiving 2331 citations.
Papers
More filters
Journal ArticleDOI
Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent
Nigel H. Greig,Tadanobu Utsuki,Tadanobu Utsuki,Donald K. Ingram,Yue Wang,Giancarlo Pepeu,Carla Scali,Qian Sheng Yu,Jacek Mamczarz,Harold W. Holloway,Tony Giordano,Demao Chen,Katsutoshi Furukawa,Kumar Sambamurti,Arnold Brossi,Debomoy K. Lahiri +15 more
TL;DR: In rats, cymserine analogs caused long-term inhibition of brain BChE and elevated extracellular ACh levels, without inhibitory effects on acetylcholinesterase, and improved the cognitive performance of aged rats.
Journal ArticleDOI
A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide.
Carsten Culmsee,Xiaoxiang Zhu,Qian Sheng Yu,Sic L. Chan,Simonetta Camandola,Zhihong Guo,Nigel H. Greig,Mark P. Mattson,Mark P. Mattson +8 more
TL;DR: Preclinical studies demonstrate the efficacy of a p53 inhibitor in models of stroke and neurodegenerative disorders, and suggest that drugs that inhibit p53 may reduce the extent of brain damage in related human neurodegenersative conditions.
Journal ArticleDOI
p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism.
Wenzhen Duan,Xiaoxiang Zhu,Bruce Ladenheim,Qian Sheng Yu,Zhihong Guo,Jon Oyler,Roy G. Cutler,Jean Lud Cadet,Nigel H. Greig,Mark P. Mattson,Mark P. Mattson +10 more
TL;DR: It is reported that two novel synthetic inhibitors of the tumor suppressor protein p53, pifithrin‐α (PFT‐α) and Z‐1‐117, are highly effective in protecting midbrain dopaminergic neurons and improving behavioral outcome in a mouse model of Parkinson's disease.
Journal ArticleDOI
Plumbagin, a Novel Nrf2/ARE Activator, Protects Against Cerebral Ischemia
Tae Gen Son,Simonetta Camandola,Thiruma V. Arumugam,Roy G. Cutler,Richard Telljohann,Mohamed R. Mughal,Tyson A. Moore,Weiming Luo,Qian Sheng Yu,Delinda A. Johnson,Jeffrey A. Johnson,Nigel H. Greig,Mark P. Mattson,Mark P. Mattson +13 more
TL;DR: In this article, a panel of botanical pesticides using cultured human and rodent neuronal cell models, and identified plumbagin as a novel potent activator of the nuclear factor E2-related factor 2 (Nrf2)/antioxidant response element (ARE) pathway.
Journal ArticleDOI
The Experimental Alzheimer's Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-β Peptide Levels in Cell Culture and Mice
Debomoy K. Lahiri,De Mao Chen,Bryan Maloney,Harold W. Holloway,Qian Sheng Yu,Tada Utsuki,Tada Utsuki,Tony Giordano,Kumar Sambamurti,Nigel H. Greig +9 more
TL;DR: Posiphen, like phenserine, can lower Aβ via multiple mechanisms and represents an interesting drug candidate for AD treatment.